Justice Department Argues For New Restrictions On Gene Patents
This article was originally published in The Gray Sheet
Executive Summary
In a move that could add uncertainty to biotechnology and diagnostic patents, the U.S. Department of Justice is arguing that isolated genes are not patentable, opposing established policy of the U.S. Patent and Trademark Office.
You may also be interested in...
Myriad's BRCA Gene Patents Struck Down In Court; Firm Downplays Impact
A federal court ruling invalidating Myriad Genetics' BRCA1 and BRCA2 cancer gene patents will have limited immediate impact on the biotech/diagnostics industry
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.